PharmTech Drug Digest 11.20
News|Articles|September 2, 2018

Pharmaceutical Technology

  • Pharmaceutical Technology-09-02-2018
  • Volume 42
  • Issue 9

Rethinking Cleaning Validation for API Manufacturing

This article focuses on applying new and traditional techniques to design a cleaning process, ensure the surfaces are clean, and develop rinse solution analysis to continuously monitor cleaning performance.

Cleaning validation is a regulatory requirement worldwide and an integral process step within the manufacturing of active pharmaceutical ingredients (APIs) and drug products. The approach of designing, qualifying, and monitoring a process is labeled a lifecycle approach. This article focuses on applying new and traditional techniques to design a cleaning process, ensure the surfaces are clean, and develop rinse solution analysis to continuously monitor cleaning performance.

Click

here

to view a PDF of this article.

Peer-Reviewed

Submitted: May 29, 2018
Accepted: June 4, 2018

About the authors

Chunfen Zhang, PhD, is a scientist in the Analytical Service & Development Group; Dijana Hadziselimovic is a technical services laboratory specialist for the Life Sciences Division; Amy Thanavaro, PhD, is a group leader scientific-Analytical Services & Development; and Paul Lopolito* is a technical services senior manager for the Life Sciences Division, Paul_Lopolito@steris.com; all are at STERIS. Adeyinka Aina, PhD, MRSC, is an innovation fellow at the Pharmaceutical Manufacturing Technology Centre, University of Limerick; and Chris Edlin, PhD, is currently director of drug development and head of Pharmaceutical Sciences in Respiratory R&D for Teva Pharmaceuticals Ireland.

*To whom all correspondence should be addressed.

Article Details

Pharmaceutical Technology
Vol. 42, No. 9
September 2018
Pages: 42–54

Citation

When referring to this article, please cite it as C. Zhang et. al, “Rethinking Cleaning Validation for API Manufacturing,” Pharmaceutical Technology 42 (9) 2018.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.